Menu

NSF to Close Overseas Offices

The agency announces that the fixed offices and staffing will be replaced with short-term expeditions to foster collaboration.

Feb 22, 2018
Shawna Williams

NATIONAL SCIENCE FOUNDATIONIn a move billed as an “upgrade” to its approach to international outreach, the US National Science Foundation (NSF) will close its three overseas offices this year, the agency announced yesterday (February 21).

The announcement comes the day after Science|Business reported that NSF had recalled the directors of its offices in Brussels and Beijing, citing budget cuts in internal announcements of the change (the third office, in Tokyo, was already without a director). The article notes that the Brussels office’s accomplishments include brokering a science cooperation agreement that makes it easier for US researchers to partner with international colleagues under the Horizon 2020 funding program, and introducing European researchers to US funding opportunities. Altogether, the three offices cost NSF about $1 million per year to run, the article estimates.

“This is the new environment we are in,” former US ambassador to the EU Anthony Gardner tells Science|Business. “All levers of soft power are being cut right now—science is just one of them. We’re beginning to see massive changes to how we do diplomacy.”

But NSF says in its statement that rather than staffing and maintaining offices, it will begin sending NSF experts “for short-term expeditions to selected areas to explore opportunities for collaboration. . . . We seek to improve cooperation by increasing outreach to our foreign counterparts instead of relying on a small number of static offices with a limited number of employees.” The office closures will take place by this summer.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.